Aspirin Impact on Platelet Reactivity in Acute Coronary Syndrome Patients on Novel P2Y12 Inhibitors Therapy
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 29
- 试验地点
- 1
- 主要终点
- Platelet reactivity
研究概览
简要总结
Thus far, no study has evaluated the impact on aspirin in addition to the newer and more potent P2Y12 inhibitors, among ACS patients and current guidelines recommend dual anti-platelet therapy consisting of aspirin and a novel P2Y12 inhibitor in this population.
Objective The investigators goal is to examine the effect of aspirin in addition to new anti-platelet agent (ticagrelor\prasugrel) on platelet reactivity in comparison with placebo, among ACS patients treated percutaneously.
Design The proposed study is a randomized-controlled, double blind trial, conducted among ACS patients treated percutaneously. Eligible patients will recruited during hospitalization due to ACS after percutaneous coronary intervention (PCI), and randomization by envelopes on 1:1 basis will take place a month after the index event, at a follow-up visit at the cardiac clinic.
Platelet function and Endothelial function tests will be taken a month after the index event, and at a 2 weeks periods following aspirin/placebo therapy, cross-over and return to open-label aspirin.
End-points platelet function tests will be compared between aspirin and placebo therapy and before and after the cross-over.
详细描述
Introduction:
Current knowledge and data support the use of dual anti-platelets for patients after acute coronary syndrome (ACS). Novel P2Y12 inhibitors have shown their superiority on clopidogrel in regarding morbidity and mortality, but at the cost of higher bleeding rates - even in lower doses of aspirin there is increase risk for gastrointestinal (GI) bleeding. In a geographical analysis of the PLATO trial it has been shown difference at outcome. When higher dose of aspirin were used, the superiority of ticagrelor was reduced.
The use of platelet reactivity tests have been proved and acknowledged in their usefulness for gauging bleeding and ischemic risks. Few studies have shown that clopidogral is inhibiting not only the ADP activity, but also the arachidonic acid (AA) pathway that is considered aspirin specific pathway. Examining the effect of potent P2Y12 inhibitors in healthy volunteers have shown increased inhibition of the AA pathway. Not only that the adding of aspirin, have shown little effect on inhibition of AA pathway.
It has been demonstrated that vascular endothelial function is inversely correlated to platelet reactivity in both individuals without established cardiovascular disease (controls) and acute myocardial infarction patients.
Objective Our goal is to examine the effect (platelet function test and endothelial function) of aspirin while added to novel P2Y12 inhibitors treated ACS patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age>18 years
- •ACS defined according to the 3rd universal definition of MI
- •PCI therapy
排除标准
- •Indication for anticoagulant therapy
- •ACS on new P2Y12 inhibitors treatment
- •Contraindication to P2Y12 therapy
- •Renal failure defined as creatinine ≥1.5 mg/dL
- •Non-compliance
- •Life-threatening extra-cardiac disease or malignancy with a life expectancy below 1 year
- •Inability to sign an informed consent
- •Participation in another trial during the previous 6 months
研究组 & 干预措施
P2Y12 inhibitors and aspirin
ACS patients on novel P2Y12 inhibitors and aspirin
干预措施: Aspirin (Drug)
P2Y12 inhibitors and placebo
ACS patients on novel P2Y12 inhibitors and placebo
干预措施: Aspirin (Drug)
结局指标
主要结局
Platelet reactivity
时间窗: one month
platelet reactivity in response to arachidonic acid
次要结局
- platelet reactivity(one month)
研究者
Dr. Shlomi Matetzky
Head of The Cardiac Intensive Care Unit
Sheba Medical Center